Re:First Blood Test for Dozens of Hereditary Cancers Approve...
by dekhn on Monday October 02, 2023 @05:50PM
(#37744943)
There's a big difference between what 23&Me includes in their technology and reports compared to solutions that are production grade medical tests. That said, 23&Me does tout their results as being medically relevant (https://www.23andme.com/brca/)
(for a while, only Myriad could do any tests with brca1/2 because they had a patent on the literal gene sequence. it went to the supreme court and the court said no, you cannot patent human gene sequences)
Re:First Blood Test for Dozens of Hereditary Cancers Approve...
by joysofpi on Monday October 02, 2023 @06:00PM
(#37745038)
they use different approaches. 23andme even has a short writeup on this: https://customercare.23andme.com/hc/en-us/articles/202904600...
Re:First Blood Test for Dozens of Hereditary Cancers Approve...
by rflrob on Monday October 02, 2023 @06:25PM
(#37745265)
23andMe works by checking ~1M sites along the genome, and using known correlations with pathogenic variants. This Invitae test actually sequences the (coding portion plus a bit of) the genes involved, and can detect rare[0] mutations. Additionally, Invitae puts a ton of effort into determining whether any particular variant (of which you certainly have very many) is benign or pathogenic.
Invitae has argued that (especially in certain under-represented populations), the 23andme approach is going to miss a lot of important variants [1].
_disclaimer: I’m a former Invitae employee and still holding the bag on what used to be a lot of stock . All opinions are my own. _
[0] Rare on the population scale. To a good approximation each person has only 0, 1, or 2 copies of any given polymorphism.
[1] https://www.biospace.com/article/invitae-challenges-accuracy...
Or are there many more variants in this test?